Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

5.7K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.7K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

235
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
235
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

170
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.

Diseases (Basel, Switzerland)·2026
Same author

Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model.

Medicina (Kaunas, Lithuania)·2026
Same author

Cutaneous Melanoma in the Context of Aging.

Medicina (Kaunas, Lithuania)·2025
Same author

Methylarginine Levels in Chronic Inflammatory Skin Diseases-The Role of L-Arginine/Nitric Oxide Pathway.

Journal of clinical medicine·2025
Same author

Microbial Signatures of Obesity-Aggravated Psoriasis: Insights from an Imiquimod-Based Mouse Model.

International journal of molecular sciences·2025
Same author

<i>FMR1</i> Methylation Pattern and Repeat Expansion Screening in a Cohort of Boys with Autism Spectrum Disorders: Correlation of Genetic Findings with Clinical Presentations.

Genes·2025

Related Experiment Video

Updated: Sep 13, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Radionuclides Landscape in Prostate Cancer Theranostics.

Monica Neagu1,2,3, Carolina Constantin1,2, Mihail Eugen Hinescu1,4

  • 1"Victor Babes" National Institute, 99-01 Splaiul Independentei, 050096 Bucharest, Romania.

International Journal of Molecular Sciences
|July 29, 2025
PubMed
Summary

Prostate cancer is common, but PSMA-targeted radiotheranostics offer new diagnostic and therapeutic options. This review explores their mechanisms, applications, and challenges in treating prostate cancer.

Keywords:
prostate cancerprostate-specific membrane antigenradionuclidesradiotherapytheranostic

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.1K

Related Experiment Videos

Last Updated: Sep 13, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

12.1K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate cancer affects millions, necessitating advanced treatment strategies.
  • Prostate-specific membrane antigen (PSMA) is a key molecular target for prostate cancer.
  • Radiotheranostics combine diagnostic imaging and targeted radionuclide therapy.

Purpose of the Study:

  • To review the molecular mechanisms of PSMA in prostate cancer.
  • To explore the clinical applications of PSMA-targeted radiotheranostics.
  • To examine the challenges in implementing these advanced therapies.

Main Methods:

  • Review of approved and investigational PSMA-targeted radiodiagnostic and radiotherapeutic agents.
  • Discussion of various radionuclides (e.g., 177Lu, 225Ac, 223Ra) and their characteristics.
  • Analysis of clinical trial data and regulatory approvals.

Main Results:

  • Several PSMA-targeted agents ([18F]DCFPyL, [18F]rhPSMA-7.3, [68Ga]Ga-PSMA-11, [177Lu]Lu-PSMA-617) are approved for prostate cancer.
  • [177Lu]Lu-PSMA-617 (PLUVICTO®) approval marks a significant advancement for metastatic castration-resistant prostate cancer.
  • Multiple radionuclides are under investigation for broader clinical implementation.

Conclusions:

  • PSMA-targeted radiotheranostics represent a significant advancement in prostate cancer management.
  • Further research and clinical trials are crucial to overcome implementation challenges.
  • These therapies hold promise for personalized treatment of prostate cancer.